

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Lutetium-177 PSMA-I&T,Lutetium (177Lu) Zadavotide Guraxetan
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : CURIUM US LLC
Deal Size : Undisclosed
Deal Type : Acquisition
Curium Completes Monrol Acquisition To Expand Lutetium-177 Capacity
Details : The acquisition enhances Curium’s manufacturing of Lutetium-177 to meet the growing demand for isotope around the world. Curium’s Lu-177 (Lutetium-177 PSMA-I&T) is being evaluated for Prostate Cancer.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Undisclosed
March 28, 2025
Lead Product(s) : Lutetium-177 PSMA-I&T,Lutetium (177Lu) Zadavotide Guraxetan
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : CURIUM US LLC
Deal Size : Undisclosed
Deal Type : Acquisition

Contact Us!